A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gotham Asset Management, LLC holds 337,009 shares of BMY stock, worth $19.5 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
337,009
Previous 286,838 17.49%
Holding current value
$19.5 Million
Previous $11.9 Million 46.41%
% of portfolio
0.19%
Previous 0.16%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $1.99 Million - $2.6 Million
50,171 Added 17.49%
337,009 $17.4 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $2.39 Million - $3.15 Million
-59,372 Reduced 17.15%
286,838 $11.9 Million
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $4.18 Million - $4.74 Million
87,060 Added 33.59%
346,210 $18.8 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $2.51 Million - $2.99 Million
51,745 Added 24.95%
259,150 $13.3 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $3.02 Million - $3.37 Million
52,110 Added 33.56%
207,405 $12 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $4.04 Million - $4.49 Million
63,449 Added 69.08%
155,295 $9.93 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $6.08 Million - $6.89 Million
-92,512 Reduced 50.18%
91,846 $6.37 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $888,322 - $1.05 Million
12,972 Added 7.57%
184,358 $13.3 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $5,948 - $3.52 Million
45,754 Added 36.42%
171,386 $12.2 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $1.33 Million - $1.47 Million
18,383 Added 17.14%
125,632 $9.67 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $435,770 - $522,527
7,088 Added 7.08%
107,249 $7.83 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $288,583 - $336,420
5,381 Added 5.68%
100,161 $6.25 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $5.34 Million - $6.25 Million
90,217 Added 1977.14%
94,780 $5.61 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $282,495 - $307,637
4,563 New
4,563 $305,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $3.95 Million - $4.44 Million
-66,597 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $4.27 Million - $4.84 Million
-74,004 Reduced 52.63%
66,597 $4.13 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $12.6 Million - $14 Million
-219,426 Reduced 60.95%
140,601 $8.48 Million
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $5.2 Million - $6.08 Million
94,928 Added 35.81%
360,027 $21.2 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $32.5 Million - $47.2 Million
-699,364 Reduced 72.51%
265,099 $14.8 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $2.99 Million - $3.9 Million
-60,747 Reduced 5.93%
964,463 $61.9 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $10.1 Million - $11.9 Million
-235,538 Reduced 18.68%
1,025,210 $52 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $15.2 Million - $16.8 Million
340,589 Added 37.01%
1,260,748 $57.2 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $30.6 Million - $36.5 Million
679,164 Added 281.82%
920,159 $43.9 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $2.24 Million - $2.91 Million
45,990 Added 23.58%
240,995 $12.5 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $5.59 Million - $6.31 Million
-101,296 Reduced 34.19%
195,005 $12.1 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $13.8 Million - $17.2 Million
273,224 Added 1183.97%
296,301 $16.4 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $7.89 Million - $9.09 Million
-131,716 Reduced 85.09%
23,077 $1.46 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $1.99 Million - $2.17 Million
33,199 Added 27.3%
154,793 $9.49 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $6.72 Million - $7.75 Million
121,594
121,594 $7.75 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.